Affiris AG: Clinical Trials

12 trials sponsored by Affiris AG, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

11 completed, 1 withdrawn. 12 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 112Completed 11, Withdrawn 1

Follow Affiris AG: new trials by email

Trials (filtered) newest first · largest first

All 12 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Follow-up Study to Assess a Second Boost Immunization With AFFITOPE® PD01A With Regard to Safety and Clinical Activity (AFF008AA)
AFFITOPE® PD01A - Parkinson's Disease
Phase 1CompletedAffiris AG262016-02-022017-06-05
Study Assessing Safety, Immunogenicity and LDLc -Lowering Activity of 2 PCSK9 Targeting AFFITOPE Vaccines in Healthy Subjects
AFFITOPE® AT04A+adjuvant, AFFITOPE® AT06A+adjuvant, Adjuvant without active component - Hypercholesterolemia
Phase 1CompletedAffiris AG722015-07-012017-10-20
Study Assessing Safety and Therapeutic Activity of AFFITOPE® PD01A and PD03A in Patients With Early MSA
AFFITOPE® PD01A + Adjuvant, AFFITOPE® PD03A + Adjuvant, Adjuvant without active component - Multiple System Atrophy, Neurodegenerative Diseases
Phase 1CompletedAffiris AG302014-12-112017-06-05
Study Assessing Tolerability and Safety of AFFITOPE® PD03A in Patients With Early Parkinson's Disease
Low dose AFFITOPE® PD03A + Adjuvant, High dose AFFITOPE® PD03A + Adjuvant, Adjuvant without active component - Parkinson Disease, Neurodegenerative Diseases
Phase 1CompletedAffiris AG362014-12-012016-10-31
Follow-up Study to Assess One Boost Immunization With AFFITOPE® PD01A With Regard to Safety and Clinical Activity
AFFITOPE® PD01A, Control - Parkinson's Disease
Phase 1CompletedAffiris AG282014-08-012015-08-17
Tolerability and Safety of Subcutaneous Administration of Two Doses of AFFITOPE® PD01A in Early Parkinson's Disease
AFFITOPE® PD01A, Control - Parkinson's Disease
Phase 1CompletedAffiris AG322012-02-012015-08-17
Safety, Immunogenicity and Dose Response of ATH03, a New Vaccine Against the Cholesterol Ester Transfer Protein (CETP)
ATH03 - HDL, Drug Safety
Phase 1CompletedAffiris AG362011-05-012012-10-05
Safety and Tolerability of AFFITOPE AD03
AFFITOPE AD03, AFFITOPE AD03 + Alum - Alzheimer's Disease
Phase 1CompletedAffiris AG282010-10-012011-12-20
Safety/Tolerability, Immunological and Clinical Activity of a Boost Immunization With AFFITOPE AD02
AFFITOPE AD02 - Alzheimer's Disease
Phase 1CompletedAffiris AG202009-10-012010-10-19
Tolerability and Safety of Subcutaneous Administration of AFFITOPE AD02 in Mild to Moderate Alzheimer's Disease
AFFITOPE AD02 - Alzheimer's Disease
Phase 1CompletedAffiris AG242008-02-012010-10-19
Tolerability and Safety of Subcutaneous Administration of Affitope AD01 in Mild to Moderate Alzheimer's Disease
AFFITOPE AD01, AFFITOPE AD01 adjuvanted - Alzheimer's Disease
Phase 1CompletedAffiris AG242007-07-012010-10-19
Study Assessing Tolerability and Safety and Exploring the Immunogenicity and Therapeutic Activity of AFFITOPE® PD01A in PD-GBA Patients
AFFITOPE® PD01A + Adjuvant, Adjuvant without active component - Parkinson's Disease
Phase 1WithdrawnAffiris AG2016-08-05

Conditions studied

Parkinson Disease (5)  ·  Alzheimer Disease (4)  ·  Neurodegenerative Diseases (2)  ·  Hypercholesterolemia (1)  ·  Inhibition, Psychological (1)  ·  Multiple System Atrophy (1)

Interventions

Adjuvants, Pharmaceutic (4)  ·  aluminum sulfate (1)

Countries

Austria (10)  ·  France (1)  ·  Germany (1)

Top investigators

Dieter Volc, Prim. Dr. (2)  ·  Achim Schneeberger, MD (1)  ·  Dieter Volc, Prim, Dr. (1)  ·  Margot Schmitz, Univ. Doz. (1)  ·  Margot Schmitz, Univ. Doz. Dr. (1)  ·  Markus Zeitlinger, MD (1)  ·  Siegfried Kasper, MD (1)  ·  Thomas Gasser, Prof. Dr. (1)  ·  Wassilios Meissner, MD, PhD (1)  ·  Werner Poewe, MD (1)

Results publications

PMID 30741694, PMID 32882100, PMID 33969434

NIH funding

2014 (3), 2015 (2), 2016 (1)